Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Alexander & Baldwin Q2 EPS $0.18 Beats $0.10 Estimate

Alexander & Baldwin (NYSE:ALEX) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $0.10 by 80 percent. This is a 357.14 percent increase over losses of $(0.07) per share from the
byBenzinga Newsdesk
July 29, 2021
1 minute read
Total
0
Shares
0
0
0
0
0
0

Alexander & Baldwin (NYSE:ALEX) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $0.10 by 80 percent. This is a 357.14 percent increase over losses of $(0.07) per share from the same period last year.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Opthea’s Phase 2B Results Of OPT-302, Anti-VEGF-C/-D “Trap” Agent Administered In Combination With Lucentis (Ranibizumab) For Wet Age-Related Macular Degeneration Have Been Published In Ophthalmology, Journal Of The American Academy Ophthalmology

By Benzinga Newsdesk
Today, 10:15 PM
The prospective, randomized, controlled Phase 2b trial of 366 treatment-naïve patients with wet AMD, demonstrated that monthly intravitreal administration of 2.0 mg OPT-302 with ranibizumab standard of care, met the

OPT